Low representation in clinical trials 'tied to real-world harms'

The issue translates into poorer survival for some women with early breast cancer, researchers say

Women with early breast cancer who are not represented at all in clinical trials of therapies are nearly three times more likely to die over five years than others who fall into groups well-represented in such trials, a study shows. 

doctors recording information on clipboard and tablet

And among patients who are represented, but poorly, in clinical trials — such as women who are not white, or aged 70 and over — the mortality risk for those with the hormone-receptor-positive/human epidermal